Joshua Summers, MD
Family Medicine · Inverness, FLNPI 1619954328
Payments from drug & device makers
Across 87 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$358
- Amgen$195
- Novo Nordisk$115
- AstraZeneca$102
- Johnson & Johnson$72
- Lilly USA, LLC$65
- plus $498 from 14 others
What the payments were for
- Food & beverage$1,38398%
- Education$232%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 22 | $358 |
| Amgen(2 entities) | 10 | $195 |
| Novo Nordisk | 8 | $115 |
| AstraZeneca | 6 | $102 |
| Johnson & Johnson | 5 | $72 |
| Lilly USA, LLC | 5 | $65 |
| Merck | 5 | $63 |
| AbbVie | 4 | $62 |
| Pfizer | 3 | $53 |
| GSK | 3 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $44 |
| Astellas Pharma US Inc | 2 | $44 |
| Eisai Inc. | 3 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Novartis | 2 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Abbott | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
How this compares
$1,406 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 195 | $200,452 |
| EliquisApixaban | 101 | $101,965 |
| JardianceEmpagliflozin | 97 | $86,485 |
| XareltoRivaroxaban | 95 | $79,462 |
| MounjaroTirzepatide | 54 | $69,508 |
| FarxigaDapagliflozin Propanediol | 76 | $58,747 |
| TrulicityDulaglutide | 30 | $46,135 |
| EntrestoSacubitril/Valsartan | 26 | $36,002 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $33,882 |
| Tresiba Flextouch U-100Insulin Degludec | 44 | $31,881 |
| Nurtec OdtRimegepant Sulfate | 13 | $26,004 |
| OxycontinOxycodone Hcl | 24 | $23,299 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $22,012 |
| Repatha SureclickEvolocumab | 28 | $20,984 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $18,475 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $115 | $200,452195 claims |
| PfizerEliquis, Nurtec Odt, Premarin | $53 | $135,592135 claims |
| Lilly USA, LLCMounjaro, Trulicity | $65 | $115,64384 claims |
| Boehringer IngelheimJardiance, Tradjenta | $358 | $100,200116 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $102 | $80,759101 claims |
| Johnson & JohnsonXarelto | $72 | $79,46295 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $49 | $52,94884 claims |
| NovartisEntresto, Exelon | $28 | $44,01037 claims |
| AbbVieVraylar, Linzess, Synthroid | $62 | $37,321135 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $37 | $18,47519 claims |
| MerckJanuvia | $63 | $18,20511 claims |
| Astellas Pharma US IncMyrbetriq | $44 | $14,02617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Inverness
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
- Dario AltamiranoHialeah$15.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.